Sufentanyl
Trigeminal Neuralgia
Xiangya Hospital of Central South UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Trigeminal Neuralgia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Neurotop Beijing Tiantan Hospital | Phase 4 | BB |
Lidocaine Beijing Tiantan Hospital | Phase 4 | BB |
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Vanderbilt University Medical Center | Phase 4 | BB |
Galcanezumab Duke University | Phase 4 | BB |
Oxcarbazepine Abbasi Shaheed Hospital | Phase 4 | BB |
View all 32 →
Same molecule, other indications
Sufentanyl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →